Related Experiment Video
Updated: Jun 4, 2026

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Interferon lambdas: the next cytokine storm.
Christabel Kelly1, Paul Klenerman, Eleanor Barnes
1Peter Medawar Building for Pathogen Research, Oxford NIHR Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, South Parks Road, Oxford OX1 3SY, UK.
Genetic variations near interferon lambda 3 (IFNλ3) influence hepatitis C virus (HCV) clearance. Research explores IFNλ3
Area of Science:
- Immunology
- Genetics
- Hepatology
Background:
- Hepatitis C virus (HCV) infection outcomes vary, with some individuals spontaneously clearing the virus while others do not.
- Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) associated with interferon lambda 3 (IFNλ3) that correlate with HCV clearance.
- These genetic associations suggest a role for IFNλ3 in viral control and treatment response.
Purpose of the Study:
- To review the genetic links between IFNλ3 and spontaneous/treatment-induced HCV clearance.
- To discuss the biological mechanisms of IFNλ3 in HCV pathogenesis.
- To examine the potential clinical applications of IFNλ3 genetic variants and exogenous IFNλ3 therapy.
Main Methods:
- Review of genetic studies, including genome-wide association studies (GWAS), linking IFNλ3 SNPs to HCV outcomes.
- Analysis of current understanding of IFNλ3 biology and signaling pathways.
- Summary of early clinical trial data on exogenous IFNλ3 treatment for HCV.
Main Results:
- Specific SNPs near the IFNλ3 gene are strongly associated with spontaneous and treatment-mediated HCV resolution.
- Exogenous IFNλ3 therapy shows potential for inhibiting HCV replication with a manageable side effect profile, though hepatotoxicity has been observed.
- Causal genetic variants and detailed IFNλ3 signaling pathways require further elucidation.
Conclusions:
- IFNλ3 genetic variants represent promising predictive biomarkers for HCV treatment outcomes.
- Understanding IFNλ3's role can inform pharmacogenomic approaches to HCV management.
- Further research is needed to define causal variants, map pathways, and optimize exogenous IFNλ3 therapy.
More Related Videos
10:00High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
09:43Microfluidic Approach to Resolve Simultaneous and Sequential Cytokine Secretion of Individual Polyfunctional Cells
Published on: March 8, 2024
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Acute Inflammation III: Local and Systemic Effects
Acute Inflammation II: Cellular Phase
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The JAK-STAT Signaling Pathway
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...